bluebird bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
02 Januar 2024 - 2:00PM
Business Wire
bluebird bio, Inc. (Nasdaq: BLUE) today announced that
Andrew Obenshain, chief executive officer, bluebird bio, will
present a corporate update at the 42nd Annual J.P. Morgan
Healthcare Conference on Tuesday, January 9, 2024, at 10:30am
PT/1:30pm ET.
To access the live webcast of bluebird bio’s presentation,
please visit the “Events & Presentations” page within the
Investors & Media section of the bluebird bio website at
http://investor.bluebirdbio.com. A replay of the webcast
will be available on the bluebird bio website for 90 days following
the event.
About bluebird bio, Inc.
bluebird bio is pursuing curative gene therapies to give
patients and their families more bluebird days.
Founded in 2010, bluebird has been setting the standard for gene
therapy for more than a decade—first as a scientific pioneer and
now as a commercial leader. bluebird has an unrivaled track record
in bringing the promise of gene therapy out of clinical studies and
into the real-world setting, having secured FDA approvals for three
therapies in under two years. Today, we are proving and scaling the
commercial model for gene therapy and delivering innovative
solutions for access to patients, providers, and payers.
With a dedicated focus on severe genetic diseases, bluebird has
the largest and deepest ex-vivo gene therapy data set in the field,
with industry-leading programs for sickle cell disease,
β-thalassemia and cerebral adrenoleukodystrophy. We custom design
each of our therapies to address the underlying cause of disease
and have developed in-depth and effective analytical methods to
understand the safety of our lentiviral vector technologies and
drive the field of gene therapy forward.
bluebird continues to forge new paths as a standalone commercial
gene therapy company, combining our real-world experience with a
deep commitment to patient communities and a people-centric culture
that attracts and grows a diverse flock of dedicated birds.
For more information, visit bluebirdbio.com or follow us
on social media at @bluebirdbio, LinkedIn,
Instagram and YouTube.
bluebird bio is a trademark of bluebird bio, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240102188681/en/
Investors: Courtney O’Leary, 978-621-7347
coleary@bluebirdbio.com
Media: Jess Rowlands, 857-299-6103
jess.rowlands@bluebirdbio.com
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
Von Mai 2023 bis Mai 2024